Dipyridamole (tablet): Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
Line 346: Line 346:
|drugBox=
|drugBox=


{{Drugbox2
| verifiedrevid = 460793850
| IUPAC_name = 2,2',2<nowiki>''</nowiki>,2<nowiki>'''</nowiki>-(4,8-di(piperidin-1-yl)pyrimido[5,4-''d'']pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol
| image = Dipyridamole.png
| image2 = Dipyridamole_ball-and-stick_animation.gif


<!--Clinical data-->
| tradename = Persantine
| Drugs.com = {{drugs.com|monograph|dipyridamole}}
| MedlinePlus = a682830
| pregnancy_category = B
| legal_UK = POM
| legal_US = Rx-only 
| routes_of_administration = oral, IV
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 99%
| metabolism = Hepatic
| elimination_half-life = Alpha (40 mins), Beta (10 Hours)
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58-32-2
| ATC_prefix = B01
| ATC_suffix = AC07
| PubChem = 3108
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00975
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2997
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 64ALC7F90C
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00302
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4653
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 932
<!--Chemical data-->
| C=24 | H=40 | N=8 | O=4
| molecular_weight = 504.626 [[Gram|g]]/[[Mole (unit)|mol]]
| smiles = n3c(nc2c(nc(nc2N1CCCCC1)N(CCO)CCO)c3N4CCCCC4)N(CCO)CCO
| InChI = 1/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
| InChIKey = IZEKFCXSFNUWAM-UHFFFAOYAG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IZEKFCXSFNUWAM-UHFFFAOYSA-N
}}


<!--Mechanism of Action-->
<!--Mechanism of Action-->

Revision as of 22:45, 13 July 2014

Dipyridamole (tablet)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dipyridamole (tablet) is a platelet aggregation inhibitor that is FDA approved for the {{{indicationType}}} of postoperative thromboembolic complications of cardiac valve replacement. Common adverse reactions include chest pain, electrocardiogram abnormalities, flushing, rash, abdominal discomfort, dizziness, headache, and dyspnea.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement
  • Dosing Information
  • The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy.
  • Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Prophylaxis of Cerebrovascular Accident
  • Developed by: ACCP
  • Class of Recommendation: Class IIb
  • Strength of Evidence: Category B
  • Dosing Information
  • 200 milligrams (mg) twice daily combined with aspirin 25 mg twice daily[1][2]

Non–Guideline-Supported Use

Peripheral Arterial Occlusive Disease
  • Dosing Information
  • 75 mg daily and aspirin 330 mg daily for 2 years[3]
Prophylaxis of Vascular Graft Occlusion
  • Dosing Information
  • 100 mg 4 times per day before the operation followed by DIPYRIDAMOLE 75 mg 3 times per day plus ASPIRIN 325 mg 3 times per day after the operation[4]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Safety and effectiveness in the pediatric population below the age of 12 years have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dipyridamole (tablet) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dipyridamole (tablet) in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Dipyridamole (tablet) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dipyridamole (tablet) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dipyridamole (tablet) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dipyridamole (tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dipyridamole (tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Dipyridamole (tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dipyridamole (tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dipyridamole (tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dipyridamole (tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dipyridamole (tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dipyridamole (tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dipyridamole (tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dipyridamole (tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Dipyridamole (tablet) in the drug label.

Condition1
  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Dipyridamole (tablet) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Dipyridamole (tablet) in the drug label.

Pharmacology

Template:Px
Template:Px
Dipyridamole (tablet)
Systematic (IUPAC) name
2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol
Identifiers
CAS number 58-32-2
ATC code B01AC07
PubChem 3108
DrugBank DB00975
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 504.626 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Protein binding 99%
Metabolism Hepatic
Half life Alpha (40 mins), Beta (10 Hours)
Excretion ?
Therapeutic considerations
Pregnancy cat.

B

Legal status

POM(UK) [[Prescription drug|Template:Unicode-only]](US)

Routes oral, IV

Mechanism of Action

Structure

File:Dipyridamole (tablet)01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dipyridamole (tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Dipyridamole (tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dipyridamole (tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dipyridamole (tablet) in the drug label.

Condition1
  • Description

How Supplied

Storage

There is limited information regarding Dipyridamole (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dipyridamole (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dipyridamole (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Dipyridamole (tablet) in the drug label.

Precautions with Alcohol

  • Alcohol-Dipyridamole (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Persantine®[5]

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Diener, H. C. (2001-04). "Cardiac safety in the European Stroke Prevention Study 2 (ESPS2)". International Journal of Clinical Practice. 55 (3): 162–163. ISSN 1368-5031. PMID 11351768. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  2. ↑ Diener, H. C. (1998-09). "Dipyridamole trials in stroke prevention". Neurology. 51 (3 Suppl 3): –17-19. ISSN 0028-3878. PMID 9744826. Check date values in: |date= (help)
  3. ↑ Hess, H. (1985-02-23). "Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial". Lancet. 1 (8426): 415–419. ISSN 0140-6736. PMID 2857803. Unknown parameter |coauthors= ignored (help)
  4. ↑ Norcott, H. C. (1982-12-27). "Platelet inhibitory drugs: an in vivo method of evaluation in patients". Thrombosis and Haemostasis. 48 (3): 307–310. ISSN 0340-6245. PMID 6761890. Unknown parameter |coauthors= ignored (help)
  5. ↑ "DIPYRIDAMOLE tablet, film coated".
  6. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Dipyridamole (tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Dipyridamole (tablet)
 |Label Name=Dipyridamole (tablet)11.png

}}


{{#subobject: 

 |Label Page=Dipyridamole (tablet)
 |Label Name=Dipyridamole (tablet)11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Dipyridamole_(tablet)&oldid=993140"